Literature DB >> 11971909

Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition.

Mohamad Aman Jairajpuri1, Aiqin Lu, Susan C Bock.   

Abstract

The mechanism for heparin activation of antithrombin III has been postulated to involve disruption of interactions between its reactive loop P1 residue and Glu(255) on the underlying protein surface. To test this hypothesis, the potential P1-constraining Arg(393)-Glu(255) hydrogen bond and ionic interactions were eliminated by converting Glu(255) to alanine. E255A and wild-type ATIIIs have identical reactive loop sequences (including the P1 and P14 residues), but differ in that Glu(255)-mediated, P1-constraining interactions with the underlying surface cannot form in the mutant. Relative to its wild-type parent, E255A had a 5-fold higher affinity for heparin and pentasaccharide. In the absence of cofactor, E255A exhibited a 5-fold activation of thrombin inhibition but no activation of factor Xa inhibition. Pentasaccharide addition elicited no further activation of thrombin inhibition but increased the factor Xa inhibition rate 100-fold. E255A heparin-dependent thrombin and factor Xa inhibition rates were 1000- and 2-fold faster, respectively, than pentasaccharide-catalyzed rates. Although "approximation" is the predominant factor in heparin activation of ATIII thrombin inhibition, and removal of the P1 constraint plays a distinct but minor role, the primary determinant for activation of factor Xa inhibition is the pentasaccharide-induced conformational change, with approximation making a further minor contribution, and removal of the P1 constraint playing no role at all.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971909     DOI: 10.1074/jbc.M203127200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Analysis of surface cavity in serpin family reveals potential binding sites for chemical chaperone to reduce polymerization.

Authors:  Poonam Singh; Mohammad Sazzad Khan; Asma Naseem; Mohamad Aman Jairajpuri
Journal:  J Mol Model       Date:  2011-06-17       Impact factor: 1.810

2.  Inhibitory properties of the P1 Tyr variant of antithrombin.

Authors:  Likui Yang; Chandrashekhara Manithody; Shabir H Qureshi; Alireza R Rezaie
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

3.  Role of P2 glycine in determining the specificity of antithrombin reaction with coagulation proteases.

Authors:  Likui Yang; Shabir H Qureshi; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Biochem Biophys Res Commun       Date:  2009-08-26       Impact factor: 3.575

4.  Serpin Inhibition Mechanism: A Delicate Balance between Native Metastable State and Polymerization.

Authors:  Mohammad Sazzad Khan; Poonam Singh; Asim Azhar; Asma Naseem; Qudsia Rashid; Mohammad Anaul Kabir; Mohamad Aman Jairajpuri
Journal:  J Amino Acids       Date:  2011-05-24

5.  Antithrombin III deficiency in Indian patients with deep vein thrombosis: identification of first India based AT variants including a novel point mutation (T280A) that leads to aggregation.

Authors:  Teena Bhakuni; Amit Sharma; Qudsia Rashid; Charu Kapil; Renu Saxena; Manoranjan Mahapatra; Mohamad Aman Jairajpuri
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 6.  Anticoagulant and signaling functions of antithrombin.

Authors:  Alireza R Rezaie; Hemant Giri
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 16.036

7.  Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides.

Authors:  Tsuyoshi Yamada; Yutaka Kanda; Makoto Takayama; Akitoshi Hashimoto; Tsutomu Sugihara; Ai Satoh-Kubota; Eri Suzuki-Takanami; Keiichi Yano; Shigeru Iida; Mitsuo Satoh
Journal:  Glycobiology       Date:  2016-01-07       Impact factor: 4.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.